Cancer vaccines tailored to fit tumor-specific profiles are at the heart of a new strategic collaboration and licensing deal between Merck & Co. Inc. and Moderna Therapeutics Inc., a company on which Merck is upping its bet as early clinical data begins to roll in as part of an earlier deal between the two targeting infectious disease.